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1. Introduction 
Matrix metalloproteinases(MMPs) are a family of zinc-containing endopeptidases which can 
degrade extracellular matrix (ECM) components at physiological PH. Thirty members of 
MMPs have been found so far [1]. They are widely distributed in plants,vertebrates and 
invertebrates cells.In human body, MMPs are mainly produced by vascular smooth muscle 
cells, monocytes, endothelial cells and so on. MMPs are synthesized as latent enzymes 
(zymogens) that are secreted or membrane-associated and must be proteolytically processed 
to their active form. Additionally, MMPs can be inhibited by endogenous inhibitors (e.g. 
TIMPs, tissue inhibitors of metalloproteinases). 
1.1 Construction and function of matrix metalloproteinases  
1.1.1 Construction of MMPs 
MMP members have similar structures. They are usually composed of six structural 
domains with different functions. 
1.2 The signal peptide and propeptide domain 
Human MMPs(except MMP14) have a signal peptide sequence. The role of the signal 
peptide is to guide the post-translation substrate to the cytoplasm endoplasmic reticulum. 
Propeptide domain contains the conserved sequence of  Pro-Arg-Cys-Gly-Val/Asn-Pro-
Asp(PRCGV/NPD) which is responsible for maintaining the stability of plasminogen. When 
the propeptide domain is cut off by the exogenous enzymes, MMPs plasminogen can be 
activated. 
1.3 The catalysis domain 
There are two zinc ion binding domains and at least one calcium binding domain in the 
catalysis domain. Of the 2 zinc ion binding domains, one is in the activation center which 
is responsible for the catalytic process of MMPs. The other one is the structural zinc ion 
domain. In the catalysis domain, both gelatinase A and B have a insertion sequence of 175 
residues. This insertion sequence is the type-fibronectin binding domain. Studies suggest 
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1.4 The hinge domain and hemopexin binding domain 
The hinge domain is located between the catalysis and the hemopexin binding domian and 
is linked with the terminal amino acid residues of the hemopexin binding domain by the 
disulfide bond. The hemopexin domain contains four duplicate sequences which has the 
weak homology with hemopexin and vitronectin. This domain is considered to be relevant 
to most MMPs' substrate specificity and also plays an important role in the integration 
between MMPs and tissue inhibitors of metalloproteinases (TIMPs). 
1.5 The transmembrane domain 
This domain exists in the carboxyl terminal of the Membrane-type MMPs(MT-MMPs) and 
can fix MT-MMPs to the cell membrane. 
MMP members have different characteristics based on the six structural domains.  
2. Function of matrix metalloproteinases 
MMPs are the essential enzymes that may play a role in the degradation of ECM in the 
connective tissue. They can degrade almost all components of ECM and play an important 
role in various physiological and pathological processes in human body. Under 
physiological conditions, MMPs participate in the process of tissue demodeling such as 
wound healing, bone resorption, pregnancy, childbirth and breast atrophy. Normal 
physiological process depends on the control and coordination between MMPs and TIMPs. 
When infection or other stimulation occurs, the expression and activation of MMP are out of 
control, which may lead to the excessive degradation of ECM. 
MMPs family can be divided into the following six categories based on the strucuture of 
their substrate, sequence simlilarity and characteristics of structural domain. 
2.1 Collagenases 
MMP-1, MMP-8,MMP-13 and MMP-18 are included. The main feature of these enzymes is 
to resolve collagen types I, II, III. Collagenase can also resolve some ECM components and 
other non-extracellular matrix molecules. 
2.2 Gelatinases 
Gelatinase A(MMP-2) and gelatinase B(MMP-9) are included. They are secreted or 
membrane-associated and must be proteolytically processed to their active form. MMP-2 
can digest gelatin, collagen types IV, V, VIII, X laminin, elastin and fibronectin. The 
molecular weight of MMP-9 is 92KD which is the largest one. MMP-9 can be synthesized by 
various cells, such as astrocytes, vascular endothelial cells, microglias, neutrophils and 
macrophages. MMP-9 is mainly affected by the regulation of plasminogen activator and its 
subsrates inclucde gelatinase, collagen types IV, V and elastin[2]. Researches have shown 
that MMP-2 and MMP-9 may play a role in angiogenesis[3], atherosclerosis[4,5] and ischemic 
brain injury[6]. 
2.3 Stromelysins 
Stromelysin-1(MMP-3) and stromelysin-2(MMP-10) have the same substrate specificity. 
However, the proteolytic efficiency of MMP-3 is higher than that of MMP-10. In addition 
to digesting extracellular matrix components, MMP-3 can also activate some pro-MMPs (e.g. 
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It is extremely important for pro-MMP-1 to produce MMP-1). MMP-11 is also called 
stromelysin-3,but it is often classified to other types because of its different structural 
sequence and substrate specificity. 
2.4 Matrilysins 
The structure of matrilysins lacks hemopexin domain. Matrilysin-1(MMP-7) and matrilysin-
2(MMP-26) are included. In addition to degrading ECM, MMP-7 can process cell surface 
factors, such as pro TNF-and E-cadherin. The matrilysin-2 (MMP-26) can also digest many 
ECM components. 
2.5 Membrane-type MMPs(MT-MMPs) 
There are six types of MT-MMPs, four types of MT-MMPs are type  I transmembrane 
protein(MMP-14,-15, -16,-24), the other two types are GPI-ankyrin(MMP-17,-25). In addition 
to MT4-MMP, all other MT-MMPs can activate pro MMP-2. These enzymes can also digest 
some ECM components. MT1-MMP(MMP-14) has the activity to degrade collagen types I, II, 
III. MT5-MMP(MMP-24) 
is mainly expressed in the cerebellum. MT6-MMP(MMP-25) is almost exclusively expressed 
in peripheral blood leucocytes, the original astrocytomas and the glioblastomas. However, it 
is not expressed in the meningiomas. 
MT-MMPs have the following characteristics: 
a. Binding with cell membrane and provide the focus area for the decomposition and 
degradation of extracellular matrix protein; 
b. In the process of migration to the cell membrane, MT-MMPs are responsible for the cell 
activation of pro convertase pathway. Therefore, different from other types of MMPs, 
MT-MMPs have the proteolytic activity once it is inserted into the cell membrane. 
c. MT-MMPs have the substrate recognition sites of other types of MMPs and participate 
in an important pathway to activate other types of MMPs. It has been proved that MT1-
MMP participates in the hydrolysis of MMP-2 and MMP-13.  
2.6 Other types of MMPs 
There are at least seven types of MMPs which are not mentioned in the prevous text. MMP-
12 is mainly expressed in macrophages and may take part in the migration of macrophages. 
MMP-12 can digest elastin and some other proteins. MMP-19 is identified through the liver 
c-DNA cloning and exists as T-cell antigens in the rheumatoid arthritis patients. Enamelysin 
(MMP-20) is mainly expressed in newly formed enamel and can digest amelogenin. The 
function of MMP-22 is not clear. MMP-23 is mainly expressed in the regeneration tissue and 
Epilysin (MMP-28) is mainly expressed in keratinocytes[7].  
3. Influence factors to the activation of matrix metalloproteinases 
The activation of MMPs is adjusted by three parts: gene transcription, zymogen activation 
and endogenous inhibitors. 
3.1 Gene transcription 
The genetic study has confirmed that there is promotor polymorphisms in MMP-1, -3, -9, -12 
which affects the expression of MMPs gene[8].The expression of MMPs mRNA is affected by 
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a variety of chemical factors, such as ECM components, carcinogens, oncogene, 
neural hormones, cytokines and corticosteroids. For example, TNF-affects the expression 
of MMPs gene by affecting the multi-cell system transcription factors (the latter is combined 
with the specific response elements in the MMPs gene enhancer);Tissue-type plasminogen 
activator (tPA) and urokinase can induce the expression of MMP-9[9,10]. The signal 
transduction mechanism of MMPs’ activation remains to be elucidated. Previous studies 
suggest that MAPK pathway may be relevant to MMPs gene expression, transcription factor 
(AP-1 and NF-KB) is closely relevant to activation of MMPs [10]. The signal transduction 
mechanisms in different types of cells or for different types of MMPs may be different. 
Mengshol et al[11] have showed that p38, JNK and NF-KB are essential for IL-1 to induce 
cartilage cells to produce MMP-13. For the production of MMP-1, p38 is still essential while  
JNK and NF-KB are not essential. Studies have also shown that some factors such as 
glucocorticoid and TGF-, can inhibit MMP gene expression at the genetic level. 
3.2 Zymogen activation 
After translation and modification, the vast majority of MMPs mRNA is secreted to ECM in 
the form of zymogen. And it will be activated after hydrolysis of the propeptide domain. 
The activation mechanism found now includes stepwise activation, activation by MT-MMP, 
and cell activation. The initial activation of MMP is often associated with plasmin 
parenzyme, elastase, kallikrein. Among them, plasmin is considered to be the most powerful 
physiological activator in human body. In addition, SH-reagent (iodoacetic acid, HOCL, 
oxidized glutathione), denaturant (urea, SDS, NaSCN) and heat treatment have the ability to 
hydrolyze propeptide domain. 
3.3 Endogenous inhibitors 
The proteolytic activity of MMP is inhibited by non-specific and specific inhibitors. Non-
specific inhibitors include 2-macroglobulin,1-antiprotease and BB-94(batimistat). 
Specific inhibitors are the tissue inhibitors of metalloproteinases(TIMPs). TIMPs, which are 
the coding proteins of multi-gene family, are the natural inhibitors of MMPs. The expression 
of TIMPs is regulated during development and tissue remodeling. To date, a total of four 
types of TIMPs have been found in vertebrates. They form the high affinity complexes with 
activated MMPs at the molar ratio of 1:1 and inhibit the degradation of ECM by blocking the 
catalysis domain of MMPs. TIMP-1 inhibits the activity of most MMPs, except for MT1-
MMP and MMP-2; TIMP-2 inhibits majority of MMPs except MMP-9. In addition, TIMP-2 
can form the complexes with MT1-MMP in the cell membrane which may have the 
regulation to activate the proteolytic activity of MMP-2; TIMP-3 inhibits MMP-1, -2, -3, -9, -13; 
TIMP-4 inhibits MMP-1, -3, -7, -9 and is highly expressed in human heart. Corresponding to 
MMPs, TIMPs play a negative role in the regulation of the ECM metabolism. They can 
prevent the activation of MMPs, inhibit the function and affect the extent of protein 
breakdown and duration of injury[12]. In some excessive matrix degradation diseases, the 
imbalance between MMPs and TIMPs leads to a net increase in overall activity of MMPs[13].   
Although TIMPs play an important role in preventing excessive matrix degradation caused 
by MMPs, recent research shows that TIMP-1 and TIMP-2 are the multifunctional proteins 
with different biological functions. It has been reported that TIMP-1 and TIMP-2 
demonstrate growth factor-like activity and inhibit the angiogenesis;while TIMP-3 is 
associated with apoptosis[7]. 
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TIMPs inhibit the MMPs activity by two steps. In the stage of zymogen activation, TIMP-2 
can form a stable complex with pro MMP-2,as well as TIMP-1 and pro MMP-9. Therefore, 
they can impede the  zymogen self-activation of pro MMP-1. In the stage of activated 
MMPs, both TIMP-1 and TIMP-2 can directly form a tight 1:1 complex with the activated 
MMPs and inhibit their activity. Naturally, the TIMP-MMP complexes may also be activated 
under certain conditions.   
4. Role of matrix metalloproteinase in cerebral ischemia 
In recent years, there is growing research interest on MMPs in central nervous system. In the 
normal central nervous system, MMP-2 and MMP-9 have been found in perivascular cells, 
brain vascular endothelial cells, astrocytes and microglias. The microglias in cultured rat can 
secrete MMP-9 once they are activated. Human hippocampal pyramidal cells can also 
synthesize MMP-9. It is reported that MMP-9 mRNA can be expressed in the developing 
mouse embryo brain, suggesting that MMP-9 is related to neurodevelopment. Studies also 
show that MMP-2 is related to the regeneration of axons. A growing number of scholars 
believe that MMPs plays an important role in the pathologic processes of central nervous 
system diseases[5].  
4.1 MMPs and pathogenesis of stroke 
Atherosclerosis is one of the underlying vascular risk factors for developing 
cerebrovascular disease. It is reported that the gelatinase of MMPs plays a key role in the 
process of intimal injury and the formation of atherosclerotic lesions. The endothelial cells 
covered on the plaque have the activity to express MMP-2 and MMP-9. The over-
expression of MMPs can dissolve collagens and significantly change the proportion of 
plaque composition which leads to the relative increase in lipid content and increases the 
plaque instability. Then the plaque cap thinningzs and splits, eventually leading to the 
occurrence of cerebral ischemia disease[14,15]. Studies have shown that MMP-8 and MMP-1, 
MMP-12 might play a decisive role in maintaining the stability of atherosclerotic 
plaques[16]. The rupture of atherosclerotic plaque partially depends on the activity and 
content of MMP-9[17]. Another study reported that the focal increase of MMP-9 activity 
was an early warning of acute plaque rupture. 
4.2 MMPs and ischemic brain injury   
In the normal state, cerebral vascular endothelial cells can not express or only express a 
small amount of MMP-9[18]. By the animal experiments, Fukuda[19] confirmed that ischemic 
brain tissue could produce some active proteases and these proteases led to the rapid and 
significant degradation of microvessels. Another studies suggested that cerebral ischemia 
and reperfusion could induce the expression of MMPs. Especially, the activity of MMP-2 
and MMP-9 would increase, which was related to cerebral microvascular permeability, 
blood-brain barrier (BBB) permeability, BBB damage, inflammatory cell invasion and 
cerebral edema[6,12,13,20]. Gidday et al[21] showed that MMP-9 in ischemic brain tissue played 
a pro-inflammatory role which helped neutrophil leukocytes migrate from the blood 
circulation into the tissue. At first, MMP-9 caused BBB damage, then MMP-9 contributed to 
the proteolysis of microvascular basement membrane and eventually led to neurological 
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damage. The possible mechanism may be the following: In the ischemic brain tissue, MMP-9 
is mainly expressed in vascular endothelial cells, the increased MMP-9 may act on the tight 
junctions and basement membrane among the BBB endothelial cells which leads to the BBB 
damage,increase of permeability and vasogenic brain edema. The worst is the occurrence of 
herniation[22]. In addition, the degradation of vascular basement membrane makes 
neutrophil leukocytes exudated to the brain tissue. MMP-2 and MMP-9 expressed by 
macrophages may contribute to their entry into the ischemic lesions and promote the 
wound healing after focal stroke [13]. However, MMP-9 expressed by neutrophil leukocytes 
may also contribute to the ischemic damage of brain. Zalewska et al[23] proposed that 
activated MMP-9 may act on a certain link of the cell apoptosis cascade in the hippocampus 
CAI area after transient ischemic brain. Previous experimental studies also showed that 
MMP-9 could degrade the myelin basic protein of brain white matter and lead to the 
damage after ischemic brain[24]. Early studies have showed that injecting MMP-2 to the rat 
brain can contribute to the opening of BBB. MMP-2 and MMP-9 destroy the capillary tight 
junctions and basement membrane by protein hydrolysis after brain ischemia, thus leading 
to vasogenic brain edema. In 1996, Rosenberg et al[25] monitored of the expression of MMP-9 
in rats with first onset cerebral infarction. They found the upregulated expression of MMP-9 
4 hours after the occlusion of middle cerebral artery,. Within 12 hours and 24 hours, the 
expression of MMP-9 in the infarction site significantly increased which was consistent with 
the peak of the vasogenic brain edema, suggesting that MMP-9 played an important role in 
secondary brain damage and vasogenic edema. Montaner' et al[26] also showed that the 
activity of MMP-9 abnormally increased in the early stage of stroke and pro-inflammatory 
response, while the activity of MMP-2 appeared in the repair phase of vascular regeneration. 
Autopsy results showed that one week after infarction, MMP-9 was expressed in 
neutrophils, and one week later the macrophages expressing matrilysin and MMP-2 were 
observed. Montaner et al also found that the level of plasma MMP-2 was higher in the 
patients with previous history of stroke. The above results suggested that MMP-9 plays an 
important role in secondary brain damage and vasogenic brain edema,while MMP-2 is 
involved in tissue repair and nerve regeneration. 
Previous studies also suggested that MMP-9 may also related to the hemorrhage translation 
after tPA or urokinase thrombolysis[24]. 
4.3 MMPs and cerebral ischemia reperfusion 
Animal model studies showed that 3 hours and 48 hours of reperfusion occurred after 
cerebral ischemia, BBB was opened and the opening reached to the peak in the 48th hour; 
The first opening was related to the increased level of MMP-2 while the second opening 
occurred in the stage when the level of MMP-9 was significantly higher; the content of 
MMP-2 reached to the peak 5 days after reperfusion and the repair process began at the 
same time; the content of TIMP-1 significantly increased in the 48th hour while that of 
TIMP-2 increased to the maximum  on day 5[12]. These results suggested that reperfusion 
may affect MMPs and TIMPs, while MMPs and TIMPs promoted the reperfusion injury 
by complex ways. When the synthetic inhibitors of MMPs (BB-1101 ) was applicated to 
inhibit MMPs, both the BBB's first opening and cerebral edema after reperfusion were 
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5. Effect of inhibiting matrix metalloproteinase on cerebral ischemia 
Matrix metalloproteinase inhibitors have been used to treat cancer metastasis. Currently, 
many MMP inhibitors are also used in experimental models of neurological diseases[6], such 
as bacterial meningitis, cerebral infarction and experimental allergic meningitis. Studies 
have shown that the content of MMPs increased after cerebral ischemia and reperfusion, 
exogenous inhibitors could reduce the ischemic and reperfusion injury[12,13]. Thus, MMPs 
may become a new potential target for stroke therapy and matrix metalloproteinase 
inhibitors can be used for treatment of cerebrovascular diseases[2].  
5.1 Matrix metalloproteinase inhibitors and cerebral ischemia  
Previous studies have showed that the activated leukocytes could increase the reperfusion 
injury in the central nervous system. So, the drugs which can inhibit the leukocyte adhesion 
(including the intracellular adherence factor antibodies) have a neuroprotective effect. 
Matrix metalloproteinase inhibitors can combine with the divalent cation in vitro, inhibit the 
leukocytes function, and reduce the reperfusion injury. 
Lee' et al[3] have shown that MMP inhibitors could inhibit the MMP-9 production in brain 
after stimulated and parenchymal angiogenesis.Horstmann[27] found that MMP-1 not only 
had the direct proteolytic capacity, but also played a role in the activation cascade of MMPs. 
It could crack  collagen types I,  II,  III  and be involved in the activation of MMP-2, MMP-9. 
Non-specific matrix metalloproteinase inhibitors are clustered in atherosclerosis tissues and 
inhibit the activity of MMP-9 in the carotid artery plaques, thereby stabilizing the easily 
broken atherosclerotic plaques. Matrix metalloproteinase inhibitors can also reduce the 
incidence of acute plaque rupture by reducing MMP-9 activity. The content of TIMPs is 
significantly higher in cerebral ischemia-reperfusion. They combine with the corresponding 
MMPs and prevent the activation of MMPs. They inhibit the function of MMPs, stabilize the 
ECM, significantly reduce the blood-brain barrier damage and the brain edema after 
ischemia[12]. 
5.2 Matrix metalloproteinase inhibitors and therapies for cerebral ischemia 
Previous studies suggested that MMP-9 monoclonal antibody may significantly reduce the 
infarction volume in a rat model of ischemia[13]. Clinical studies have also confirmed that 
MMP-9 is related to the total infarction volume. It is reported that matrix metalloproteinase 
inhibitors and MMPs neutralizing antibodies can reduce the vasogenic brain edema and 
infarction volume[26]. In addition, MMPs inhibitors are also effective in preventing 
atherosclerosis and the ischemic brain damage.  
rt-PA and urokinase are effective drugs for acute ischemic stroke. However,  the clinical 
application of thrombolytics is limited by the narrow therapeutic time window and the 
complication of bleeding after thrombolysis. But if we combine rt-PA or urokinase with the 
MMP inhibitors (BB-94 or doxycycline)in thrombolysis treatment, the incidence of 
hemorrhage and the amount of hemorrhage after thrombolysis may be decreased and the 
thrombolytic time window will be prolonged[28,29]. This is because that if MMPs inhibitors 
are used before the application of rt-PA or urokinase, MMP-2, MMP-3 and MMP-9 (which 
have the potential damage for BBB) would be inhibited. BBB would be closed and the 








MMPs may play an important role in the brain ischemia and reperfusion by degrading the 
ECM and destroying the blood -brain barrier which can lead to the vasogenic brain edema 
and secondary brain injury. The matrix metalloproteinase inhibitors and MMPs neutralizing 
antibodies can reduce the vasogenic brain edema and infarction volume. In addition, MMPs 
inhibitors are also effective in preventing atherosclerosis and the ischemic brain damage. 
Thus, MMPs may become a new potential target for stroke therapy and matrix 
metalloproteinase inhibitors can be used for the treatment of cerebrovascular diseases. 
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